Bayer has again reached out to DKSH to expand its presence in Asia, this time tasking the Swiss company with helping it push its therapies in Singapore.
Big Pharma has fought bruising battles in India over intellectual property. China has added compulsory licensing to its bag of tricks for dealing with costly drugs. Now drugmakers can add South Africa to the list of countries that are looking askance at unimpeded patents.
India, facing its worst economic crisis in two decades, has in recent years invested little in basic infrastructure like power, water and roads. These shortcomings are forcing some of its most successful drugmakers to look outside the country when they need new manufacturing sites.
While many Big Pharma players have only recently discovered the potential of doing business in Russia, India's generic drugmaker Ranbaxy Laboratories has been there for two decades. Ranbaxy has established itself by selling the low-price copycat drugs it has made its fortunes on, but is now looking at moving up the value chain.
GlaxoSmithKline is in the middle of a firestorm in China, accused of bribery and potentially facing massive fines from the government. The very public scandal has left a chill on business for it and other drugmakers in this key market. But even with all of that, would the British drugmaker actually pull out of the most populous country in the world, on which it has bet heavily?
India finally granted Mylan the go-ahead this week to complete the buyout of the sterile-injectables unit of Strides Arcolab. But in Vermont the big news is the much more modest expansion of Mylan's transdermal patch facility in St. Albans.
Nonprofit PATH has come under attack this week after a parliamentary committee accused it of subterfuge in a human papillomavirus vaccine project that gave GlaxoSmithKline's Cervarix and Merck's Gardasil to girls in two Indian states.
It's never good when authorities talk openly of imposing "astronomical" fines on a drugmaker. But China officials have suggested that about GlaxoSmithKline, even as a spray of Chinese news reports accuse former GSK China leader Mark Reilly of fostering a culture that encouraged doing whatever neccessary to hit huge sales goals.
Contrary to GlaxoSmithKline 's official explanations, Chinese police say rogue executives didn't engineer $489 million in alleged bribes. The company itself organized the scheme, they say, and made sure internal auditors didn't uncover it.
GlaxoSmithKline may not have to close a former Europharm plant in Romania that it no longer needs. It may be able to sell it instead.